By Neil W. Draisin, OD
Neil W. Draisin, OD, of Draisin Vision Group in Charleston, S.C., explains why gaining the buy-in of new optometric partners is essential to making things work. Critical to mutual success is offering new partners a fair deal with perks such as bonuses and annuities.
By Evan Kestenbaum, MBA
When organizing your frame board, what works and what doesn’t should not be a mystery. Measuring the mix of frames that works best is your first step to better serving your patients.
By Jason Miller, OD
You have an opportunity to help children and teen patients improve their vision and build family loyalty to your practice by moving more young people into contact lenses.
By Jason Daniels
Search engine optimization may be easier said than done. ROB and EyeCarePro.net found questions streaming in following the Jan. 31 webinar, “Search Engine Optimization: How to Rank #1 on Google.” Jason Daniels, webinar host and director of professional services for EyeCarePro.net, offers action plans to address your top questions.
ROB Fast Fact
More than 50 Percent of Optical Retailers…
>Some 54 percentof independent retailers agree with the statement, “I promote the use of progressive lenses to all my presbyopic patients, including those who currently wear bifocals or trifocals,” according toJobson Research’s 2010 Premium Lenses MarketPulse Survey, which can be purchasedby clicking here.When asked about familiarity regarding new progressive lens technologies, 89 percentof 237 respondents were aware of the terms “freeform” and “customized.” Eighty-fourpercent were aware of the term “personalized,” and only 57 percentwere aware of the term “contrast enhancing.”
Consumer Price Index
The Consumer Price Index for All Urban Consumers increased 0.4 percent in April on a seasonally adjusted basis, the U.S. Bureau of Labor Statistics reported. Over the last 12 months, the all items index increased 3.2 percent before seasonal adjustment. The index for all itemsrose 0.2 percent in April, the third increase of that size in the last four months. Indexes making major contributions to that increase included those for new vehicles, used cars and trucks, medical care and shelter. The 12-month increases of major indexes continue to climb. The all items index rose 3.2 percent for the 12 months ending April 2011, the highest figure since October 2008. >>READ BLS Report>>
Cheaper Drug to Treat Macular Degeneration is Effective
A drug that costs about $50 a dose is just as effective at preserving and improving vision in elderly people with macular degeneration as $2,000-a-dose Lucentis, the New York Times reported. The trial compared the effectiveness of Lucentis, a drug approved to treat one form of macular degeneration, with Avastin, a cancer drug that many eye doctors have been using off-label instead of Lucentis because of its far lower cost. The drugs, both made by Genentech, work in a similar manner. The findings could possibly save Medicare hundreds of millions of dollars a year. “Health-care providers and payers worldwide will now have to justify the cost of using” Lucentis, Dr. Philip J. Rosenfeld, a retina specialist at the University of Miami, wrote in an editorial in the The New England Journal of Medicine, which published the trial results online. >>READ NY Times Article>>